TNFSF13 and lymphoma: About 50% of DLBCL cases show increased levels of neutrophil-derived APRIL, a proliferation-inducing TNF ligand, also known as TALL-2, a proliferation-inducing ligand that may worsen lymphoma aggressiveness.